Compare Summit Therapeutics Inc (SMMT) vs SMX Security Matters plc (SMX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Summit Therapeutics Inc vs SMX Security Matters plc — how do they compare? Summit Therapeutics Inc trades at $17.55 (market cap $13.79B), while SMX Security Matters plc trades at $17.93 (market cap $19.09M). The key difference: Summit Therapeutics Inc is far larger — about 722.4× SMX Security Matters plc's market cap, and Summit Therapeutics Inc is trading nearer its 52-week high, SMX Security Matters plc nearer its low. Which is the better fit depends on your goals.
| SMMT | SMX | |
|---|---|---|
Market Cap | $13.79B | $19.09M |
Sector | Health | Technology |
52-Week High | $26.38 | $74.08K |
52-Week Low | $12.43 | $12.87 |
Enterprise Value | $13.11B | -$12.23M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Summit Therapeutics (SMMT) trades at $17.28, down 1.85% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of $1.08 billion for 2025, negative ROE of -192.5%, and relies on financing cash flow for liquidity. Recent news highlights positive Phase III trial results for ivonescimab in lung and biliary tract cancers, driving investor optimism ahead of a key FDA decision in November 2026.
The outlook hinges on regulatory approval and commercial success of ivonescimab, with a consensus price target of $25.23 implying 46% upside. Risks include high cash burn, clinical trial uncertainties, and potential dilution from financing activities. Analyst sentiment is bullish (60.9% buy ratings), but the stock remains speculative due to its pre-revenue status and dependence on pipeline milestones.
SMX trades at $17.88, down 8.21% on the day, with a bullish technical signal from moving averages and oscillators. The company reported a net loss of $169.18 million for 2025, with negative cash flow from operations but positive net cash flow due to financing. Recent news highlights expansion of its digital material passport platform for plastics and precious metals, targeting sustainability and supply chain verification markets.
The outlook hinges on commercialization success amid steep losses. Opportunities exist in regulatory tailwinds for recycled materials, but high cash burn and negative ROE pose significant risks. Investor sentiment is cautiously optimistic due to technology potential, yet profitability remains a distant milestone.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →About SMX Security Matters plc
SMX Security Matters plc is a digital authentication and tracking technology company that uses a chemical-based, invisible marker system to trace and verify products across global supply chains. Their technology creates a 'digital twin' of physical products, used for quality control, counterfeiting prevention, and ensuring sustainability compliance from raw materials to final sale. The company's solutions are applied across various industries, including precious materials, luxury goods, and fast-moving consumer goods.
Read more on SMX →
